ClinicalTrials.gg
CompletedNCT06137742Updated Aug 21, 2026

A Study to Learn About the Study Medicine Called PF-07868489 in Healthy Adult People and in People With Pulmonary Arterial Hypertension

A Phase 1/2 interventional study of PF-07868489 and Placebo for PF-07868489 in Pulmonary Arterial Hypertension, sponsored by Pfizer. Completed at 46 sites in 12 countries. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-21.

Sponsored by Pfizer · Phase 1/2, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
97
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Pulmonary Arterial Hypertension by Pfizer — none open to participants now, none under way, none of them phase 3. Pulmonary Arterial Hypertension · Pfizer.

Started
2023
the only one that year
Phase 1/2
Only one
of the 11
Registered
11th of 11
by date

Among the 11 studies in Pulmonary Arterial Hypertension by Pfizer, this one is the only one that started in 2023, is the only one in phase 1/2, and was the 11th registered.

Pulmonary Arterial Hypertension

700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Open to participants now

None of the 11 studies in Pulmonary Arterial Hypertension by Pfizer is open now. The open studies under Pulmonary Arterial Hypertension, anywhere →

Who these studies take

Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Pulmonary Arterial Hypertension by Pfizer as a file.
02

Study summary

The purpose of the study is to learn how the study medicine called PF-07868489 is tolerated and acts in healthy adult people and people with pulmonary arterial hypertension (PAH).

Part A:

An investigator- and participant-blind, sponsor-open, placebo-controlled, single ascending dose study to assess the safety, tolerability, and pharmacokinetics (PK) of PF-07868489 in healthy adult participants.

Part B:

A 24-week, randomized, double blind, placebo-controlled study to assess the safety, tolerability, PK, and pharmacodynamics (PD) of PF-07868489 in adult participants with PAH.

03

Conditions studied

  • Pulmonary Arterial Hypertension

Keywords

  • pulmonary
  • high lung artery pressure
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria Part A:

  • overtly healthy
  • (BMI) of 16 to 32 kg/m2; and a total body weight >50 kg.

Key Exclusion Criteria Part A:

  • hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, infections or allergic disease.
  • smoking more than 10 cigarettes (or equivalent) per day or smoking history ≥10 pack-years.

Key Inclusion Criteria Part B:

  • diagnosis of pulmonary arterial hypertension (PAH)
  • stable dose of standard of care PAH vasodilators
  • BMI 16 to 40 kg/m2; and a total body weight >45 kg.
  • 6MWD ≥ 150 and ≤ 450.
  • Pre-randomization RHC documenting a minimum of PVR ≥ 400 dyn ∙sec/cm5.

Key Exclusion Criteria Part B:

  • Any medical or psychiatric condition or laboratory abnormality.
  • Stopped receiving pulmonary hypertension chronic general supportive therapy 90 days prior to Day 1.
  • Pulmonary capillary wedge pressure > 15 mmHg on right heart catheterization (RHC) conducted during Screening.
  • History of severe allergic or anaphylactic reaction or to recombinant proteins or in product.
  • Major surgery within 8 weeks prior to randomization.
  • Participants who smoke more than 10 cigarettes (or equivalent) per day or has a smoking history ≥10 pack-years.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
97 participants (actual)

Study arms

  • Experimental
    PF-07868489

    single subcutaneous injection (Part A); 6 subcutaneous injections at regular intervals (Part B)

    Drug: PF-07868489

  • Placebo comparator
    Placebo

    single subcutaneous injection (Part A); 6 subcutaneous injections at regular intervals (Part B)

    Drug: Placebo for PF-07868489

Interventions

  • DrugPF-07868489

    Experimental Treatment

  • DrugPlacebo for PF-07868489

    Placebo

06

What researchers measure

Primary outcomes

  1. Number of Participants with Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Part A

    Time frame: Baseline up to Day 113.

  2. Number of Participants With Change From Baseline in Laboratory Tests Results

    Part A

    Time frame: Baseline up to Day 113

  3. Number of Participants With Vital Sign Abnormalities

    Part A

    Time frame: Baseline up to Day 113

  4. Number of Participants With Change From Baseline in Electrocardiogram (ECG) Parameters

    Part A

    Time frame: Baseline up to Day 113

  5. Number of Participants with Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Part B

    Time frame: Baseline up to Day 253

  6. Number of Participants With Change From Baseline in Laboratory Tests Results

    Part B

    Time frame: Baseline up to Day 253

  7. Number of Participants With Vital Sign Abnormalities

    Part B

    Time frame: Baseline up to Day 253

  8. Number of Participants With Change From Baseline in Electrocardiogram (ECG) Parameters

    Part B

    Time frame: Baseline up to Day 253

  9. Change From Baseline in Pulmonary Vascular Resistance (PVR) at Week24

    repeated doses

    Time frame: Baseline, Week 24

Secondary outcomes

  1. Area Under the Plasma Concentration-time Profile From Time Zero to the Time of Last Quantifiable Concentration (AUClast)

    single dose

    Time frame: Pre dose, 8, 12, 24, 48,72,96,168,336 hours post dose

  2. Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf)

    single dose

    Time frame: Pre dose, 8, 12, 24, 48,72,96,168,336 hours post dose

  3. Maximum Observed Plasma Concentration (Cmax)

    single dose

    Time frame: Pre dose, 8, 12, 24, 48,72,96,168,336 hours post dose

  4. Time to Reach Maximum Observed Plasma Concentration (Tmax)

    single dose

    Time frame: 4-7 days

  5. Incidence of Anti-Drug Antibody (ADA)

    single dose

    Time frame: Baseline and up to week 16

  6. Plasma Decay Half-Life (t1/2)

    single dose

    Time frame: Day 113

  7. Minimum Observed Plasma Trough Concentration (Cmin)

    repeat doses

    Time frame: Day 253

  8. Plasma Decay Half-Life (t1/2)

    repeat doses

    Time frame: Day 253

  9. Incidence of Anti-Drug Antibody (ADA)

    repeated doses

    Time frame: Baseline and up to Day 253

  10. Change From Baseline in N-Terminal Prohormone Brain Natriuretic Peptide (NT-proBNP) Concentration at Week24

    repeated doses

    Time frame: Baseline, Week 24

  11. 6MWD

    repeated doses

    Time frame: Baseline, Week 24

07

Study locations

46 sites
  • Anaheim Clinical Trials, LLC
    Anaheim, California 92801, United States
  • UCI Health - Costa Mesa
    Costa Mesa, California 92627, United States
  • UCI Health Center for Innovative Health Therapies (CIHT)
    Orange, California 92868, United States
  • University of California, Irvine Medical Center
    Orange, California 92868, United States
  • UCSF Health St. Mary's Hospital
    San Francisco, California 94117, United States
  • UCSF Helen Diller Medical Center at Parnassus Heights
    San Francisco, California 94143, United States
  • Icahn school of medicine at Mount Sinai
    New York, New York 10029, United States
  • Mount Sinai Hospital
    New York, New York 10029, United States
  • Eastowne 100 Medical Office Building
    Chapel Hill, North Carolina 27514, United States
  • Eastowne Medical Office Building - Clinical Research Unit
    Chapel Hill, North Carolina 27514, United States
  • UNC Health - Eastowne Medical Office
    Chapel Hill, North Carolina 27514, United States
  • UNC Hospitals
    Chapel Hill, North Carolina 27514, United States
  • Investigational Drug Services Pharmacy
    Morrisville, North Carolina 27560, United States
  • Medical University of South Carolina - Nexus
    Charleston, South Carolina 29425, United States
  • Medical University of South Carolina - Radiology
    Charleston, South Carolina 29425, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • Royal Prince Alfred Hospital
    Camperdown, New South Wales 2050, Australia
  • Pulmonary Hypertension Research Queensland Pty Ltd
    Auchenflower, Queensland 4066, Australia
  • Wesley Research Institute
    Auchenflower, Queensland 4066, Australia
  • Université Libre de Bruxelles - Hôpital Erasme
    Brussels, Bruxelles-capitale, Région de 1070, Belgium
  • UZ Leuven
    Leuven, Vlaams-brabant 3000, Belgium
  • Guangdong Provincial People's Hospital
    Guangzhou, Guangdong 510080, China
  • The Second Xiangya Hospital of Central South University
    Changsha, Hunan 410011, China
  • Zhongda Hospital Southeast University
    Nanjing, Jiangsu 210009, China
  • Shanghai Pulmonary Hospital
    Shanghai, Shanghai Municipality 200433, China
  • Vseobecna fakultni nemocnice v Praze
    Prague, 12808, Czechia
  • CHRU de Brest
    Brest, Finistère 29200, France
  • CHRU de Brest
    Brest, Finistère 29609, France
  • Centre Hospitalier Universitaire de Saint Étienne - Hôpital Nord
    Saint Priest En Jarez, Pays de la Loire Region 42270, France
  • Thoraxklinik-Heidelberg gGmbH
    Heidelberg, Baden-Wurttemberg 69126, Germany
  • Universitätsklinikum Regensburg
    Regensburg, Bavaria 93053, Germany
  • UKGM Gießen/Marburg
    Giessen, Hesse 35392, Germany
  • Universitätsmedizin Greifswald
    Greifswald, Mecklenburg-Vorpommern 17475, Germany
  • Universitaetsklinikum Carl Gustav Carus, Technischen Universitaet Dresden
    Dresden, Saxony 01307, Germany
  • Fondazione IRCCS Policlinico San Matteo
    Pavia, 27100, Italy
  • Kobe University Hospital
    Kobe, Hyōgo 650-0017, Japan
  • St. Marianna University Hospital
    Kawasaki, Kanagawa 216-8511, Japan
  • Tohoku University Hospital
    Sendai, Miyagi 980-8574, Japan
  • National Hospital Organization Okayama Medical Center
    Okayama, 701-1154, Japan
  • Gachon University Gil Medical Center
    Namdong-gu, Incheon-gwangyeoksi [incheon] 21565, South Korea
  • Seoul National University Hospital
    Seoul, Seoul-teukbyeolsi [seoul] 03080, South Korea
  • Severance Hospital, Yonsei University Health System
    Seoul, Seoul-teukbyeolsi [seoul] 03722, South Korea
  • Samsung Medical Center
    Seoul, Seoul-teukbyeolsi [seoul] 06351, South Korea
  • Hospital Universitario La Paz
    Madrid, Madrid, Comunidad de 28046, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, 28041, Spain
  • Hammersmith Hospital
    London, London, CITY of W12 0HS, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2023 to primary completion in Jul 2026, 32 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2023
First posted
Nov 18, 2023
StartActual
Nov 17, 2023
Primary completionActual
Jul 31, 2026
CompletionActual
Jul 31, 2026
Last update
Aug 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06137742
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Nov 18, 2023
Start date
Nov 17, 2023
Primary completion
Jul 31, 2026
Completion
Jul 31, 2026
Last update
Aug 21, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion